Ortho Clinical Diagnostics
Ortho Clinical Diagnostics, a leading player in the in vitro diagnostics industry, is headquartered in the United States. Founded in 1939, the company has established itself as a pioneer in blood testing and transfusion diagnostics, serving healthcare providers across the globe. With a strong presence in North America, Europe, and Asia, Ortho Clinical Diagnostics focuses on delivering innovative solutions that enhance laboratory efficiency and patient care. The company’s core offerings include advanced blood screening, clinical chemistry, and immunoassay systems, distinguished by their accuracy and reliability. Notable achievements include the development of the first FDA-approved blood screening test for HIV. With a commitment to quality and innovation, Ortho Clinical Diagnostics continues to solidify its market position as a trusted partner in the healthcare sector, driving advancements in diagnostic technology.
DitchCarbon Score
How does Ortho Clinical Diagnostics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ortho Clinical Diagnostics's score of 26 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ortho Clinical Diagnostics's reported carbon emissions
In 2022, Ortho Clinical Diagnostics reported a total of approximately 45,291,000 kg CO2e in combined Scope 1 and Scope 2 emissions. The previous year, 2021, saw emissions of about 45,291,000 kg CO2e, with Scope 1 emissions at approximately 17,320,000 kg CO2e and Scope 2 emissions at around 27,971,000 kg CO2e. In 2020, the company recorded similar figures, with total emissions of about 45,807,000 kg CO2e, comprising approximately 19,409,000 kg CO2e from Scope 1 and about 26,398,000 kg CO2e from Scope 2. Ortho Clinical Diagnostics has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. Additionally, the company plans to achieve a 30% reduction in its Scope 1 GHG emissions from 2022 levels by 2030, as well as a similar 30% reduction in Scope 2 emissions by the same year. These targets reflect the company's commitment to sustainability and its proactive approach to addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 19,409,000 | 00,000,000 |
| Scope 2 | 26,398,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ortho Clinical Diagnostics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
